Skip to main content

Melissa J. Brayman, PhD


[email protected]



Melissa’s practice focuses on the preparation and prosecution of US and international patent applications. A registered patent attorney, Melissa has managed patent portfolios involving a wide range of technologies, including biofuels, personalized medicine, cancer therapeutics, tissue grafts, biological products, immunology, plant biotechnology, and stem cells.

Her experience includes preparing freedom to operate and patentability reports for biotechnology and pharmaceutical clients, conducting due diligence and evaluating patent portfolios in preparation for capital investment, preparing memoranda on inventorship, and interviewing cases at the USPTO. Prior to joining Mintz, she was an associate in the San Diego office of another international law firm.

Before she earned her law degree, Melissa was a postdoctoral fellow at UC San Diego, where she studied the regulation of hypothalamic GnRH neurons by steroid hormones. Her PhD thesis was titled, “Progesterone Regulation of the Human MUC1 Gene in Uterine Epithelial Cells.” She also earned an MBA with a concentration in new venture creation.

In addition to her intellectual property practice, Melissa has an active pro bono practice, and has worked on a number of immigration cases for pro bono clients.


  • University of San Diego School of Law (JD, magna cum laude)
  • University of Delaware (PhD, Biological Sciences)
  • University of Delaware (MBA)
  • University of Delaware (BA, Biological Sciences)

Recognition & Awards

  • Order of the Coif
  • CALI Awards: Property, Evidence, Corporations, and Public International Law


  • Chair, Industrial Biotechnology Subcommittee, Biotechnology Committee of the American Intellectual Property Law Association (2016 – present)
  • Co-chair, Mintz Pride Steering Committee


When Public Use Qualifies for the Experimental Use Exception to 35 U.S.C. § 102(b)

July 24, 2018 | Blog | By Marc Morley, Melissa Brayman

Some inventions require testing before they are ready for patenting, and sometimes that testing requires use by the public. A recent decision from the Federal Circuit provides additional guidance on what activities qualify for the experimental use exception to the public use bar of 35 U.S.C. § 102(b).